Polyunsaturated fatty acid supplementation for ADHD? Fishy, fascinating, and far from clear

Journal of Developmental and Behavioral Pediatrics

Volumn 28, Issue 2, 2007, Pages 139-144

  Busch, Betsy ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ASCORBIC ACID; ATOMOXETINE; BEHENIC ACID; BIOLOGICAL MARKER; CENTRAL STIMULANT AGENT; DOCOSAHEXAENOIC ACID; DOPAMINE; FISH OIL; ICOSANOID; ICOSAPENTAENOIC ACID; LINOLEIC ACID; MEMBRANE PHOSPHOLIPID; NORADRENALIN; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PLACEBO; POLYUNSATURATED FATTY ACID; SEROTONIN;

ATTENTION DEFICIT DISORDER; BRAIN DEVELOPMENT; BRAIN FUNCTION; CHILD DEVELOPMENT; CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIET SUPPLEMENTATION; DOPAMINE RELEASE; DRUG WITHDRAWAL; DRY SKIN; ERYTHROCYTE MEMBRANE; HUMAN; HYPOTHESIS; MANIA; MENTAL DISEASE; NORADRENALIN RELEASE; NOTE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEROTONIN RELEASE; SYMPTOMATOLOGY; UNSPECIFIED SIDE EFFECT; VISION;

ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BRAIN; CHILD; DIAGNOSIS, DIFFERENTIAL; DOCOSAHEXAENOIC ACIDS; FATTY ACIDS, OMEGA-3; FATTY ACIDS, UNSATURATED; FEMALE; FISHES; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 34247220327     PISSN: 0196206X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.DBP.0000267560.34199.e0     Document Type: Note

References (31)

1. Sinn N, Bryan J. Effect of supplementation with polyunsaturated fatty acids and micronutrients on learning and behavior problems associated with child ADHD. Dev Behav Pediatr. 2007;28:82-91.
2. Hallahan B, Garland MR. Essential fatty acids and mental health. Br J Psychiatry. 2005;186:275-277.
3. Marszalek JR, Lodish HF. Docosahexaenoic acid, fatty acid-interacting proteins, and neuronal function: breastmilk and fish are good for you. Annu Rev Cell Dev Biol. 2005;21:633-657.
4. Chalon S, Vancassel S, Zimmer L, et al. Polyunsaturated fatty acids and cerebral function: focus on monoaminergic neurotransmission. Lipids. 2001;36:937-944.
5. Chen C, Bazan NG. Lipid signaling: sleep, synaptic plasticity and neuroprotection. Prostaglandins Other Lipid Mediat. 2005;77:65-76.
6. Vaddadi K Essential fatty acids and mental illness. Int Rev Psychiatr. 2006;18:81-84.
7. Uauy R, Hoffman DR, Peirano P, et al. Essential fatty acids in visual and brain development. Lipids. 2001;36:885-895.
8. Li D, Weisinger HS, Weisinger RS, et al. Omega-6 to omega-3 fatty acid imbalance early in life leads to persistent reductions in DHA levels in glycerophospholipids in rat hypothalamus even after long-term omega-3 fatty acid repletion. Prostaglandins Leukot Essent Fatty Acids. 2006;74:391-399.
9. McNamara RK. The emerging role of omega-3 fatty acids in psychiatry. Prostaglandins Leukot Essent Fatty Acids. 2006;75:223-225.
10. Eaton SB, Eaton SB 3rd, Sinclair AJ, et al. Dietary intake of longchain polyunsaturated fatty acids during the paleolithic. World Rev Nutr Diet. 1998;83:12-23.
11. Simopoulos AP. Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implications for chronic diseases. Biomed Pharmacother. 2006;60:502-507.
12. Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res. 1998;30:193-208.
13. Horrobin DF. The possible roles of prostaglandin E1 and of essential fatty acids in mania, depression and alcoholism. Prog Lipid Res 1981;20:539-541.
14. Schachter H, Kourad K, Merali Z, et al. Effects of omega-3 fatty acids on mental health. Evidence report/technology assessment no. 116. AHRQ Publication No. 05-E022-2. Rockville, MD: Agency for Healthcare Research and Quality. July 2005. Available at: http://www.ahrq.gov/downloads/pub/evidence/pdf/o3mental/ o3mental.pdf. Accessed December 1, 2006.
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition. Washington, DC: American Psychiatric Association; 1980.
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association, 1987.
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
18. Richardson AJ. Long-chain polyunsaturated fatty acids in childhood developmental and psychiatric disorders. Lipids 2004;39:1215-1222.
19. Antalis CJ, Stevens LJ, Campbell M, et al. Omega-3 fatty acid status in attention-deficit/hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids. 2006;75:299-308.
20. Stevens LJ, Zhang W, Peck L, et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids. 2003;38:1007-1021
21. Young GS, Maharaj NJ, Conquer JA. Blood phospholipid fatty acid analysis in adults with and without attention deficit/hyperactivity disorder. Lipids. 2004;39:117-123.
22. Voigt RG, Llorente CL, Jensen JK, et al. A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J Pediatr. 2001;139:189-196.
23. Joshi K, Lad S, Kale M, et al. Supplementation with flax oil and vitamin C improves the outcome of attention deficit hyperactivity disorder (ADHD). Prostaglandins Leukot Essent Fatty Acids. 2006;74:17-21.
24. Hamazaki T, Hirayama S. The effect of docosahexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo controlled double-blind study. Eur J Clin Nutr. 2004;58:838.
25. Richardson AJ, Puri BK. A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning disabilities. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:233-239.
26. Richardson AJ, Montgomery P. The Oxford-Durham Study: a randomized, controlled study of dietary supplementation with fatty acids in children with developmental coordination disorder. Pediatrics. 2005;115:1360-1366.
27. Wolraich ML, Hannah JN, Baumgaertel A. Examination of DSM-IV criteria for attention deficit/hyperactivity disorder in a countywide sample. J Dev Behav Pediatr. 1998;19:162-168.
28. Gordon M, Antshel K, Faraone SV, et al. Symptoms versus impairment: the case for respecting DSM-IV's criterion D. J Atten Disord. 2006;9:465-475.
29. Jensen PS, Hinshaw SP, Swanson JM, et al. Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers. J Dev Behav Pediatr. 2001;22:60-73.
30. Ward PE. Potential diagnostic aids for abnormal fatty acid metabolism in a range of neurodevelopmental disorders. Prostaglandins Leukot Essent Fatty Acids. 2000;63:65-68.
31. Castellanos FX, Lee PP, Sharp W, et al. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/ hyperactivity disorder. JAMA. 2002;288:1740-1748.